Today: 7 February 2026
Subscribe
Browse Category

XETRA:MRK News 27 June 2025 - 9 January 2026

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Why Immunome stock is up today: IMNM jumps 7% as biotech firms up and JPM conference looms

Immunome shares rose 7.4% to $21.97 Friday after recent Phase 3 data showed its lead drug varegacestat cut disease progression or death by 84% in desmoid tumor patients. The company plans to file for FDA approval in Q2 2026. Immunome also granted stock options to three new hires and will present at the J.P. Morgan Healthcare Conference on Jan. 14.
9 January 2026
···
Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3
27 June 2025
···········

Stock Market Today

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

Linde stock price falls as LIN heads into weekend; JPMorgan downgrade and guidance in focus

7 February 2026
Linde plc shares fell 2.5% to $448.24 Friday after reporting Q4 sales up 6% to $8.76 billion and adjusted EPS of $4.20. The company guided 2026 adjusted EPS to $17.40–$17.90, below analyst consensus. JPMorgan downgraded the stock, while Morgan Stanley and UBS raised price targets. Linde repurchased $1.4 billion in shares in Q4 and returned $7.4 billion to shareholders in 2025.
GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

GE Vernova stock closes up nearly 6% — what to watch before Monday’s trade

7 February 2026
GE Vernova shares jumped 5.6% to $779.35 Friday as Wall Street rallied and the company reported 1.1 GW of U.S. wind repower orders for 2025. The company also closed its $5.3 billion purchase of the remaining Prolec GE stake and completed a $2.6 billion senior notes offering. Investors await next week’s U.S. jobs and inflation data.
Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

Citi stock jumps 6% as consent-order exit talk builds — what to watch next week

7 February 2026
Citigroup shares rose 6% to $122.69 at Friday’s close after a Reuters report said executives are more optimistic about completing key consent orders this year. Citi also announced a $2.3 billion preferred stock redemption and a matching program for employee “Trump Accounts.” Investors await next week’s U.S. economic data and Citi conference appearances.
Go toTop